Dr. Reddy's Laboratories Ltd (RDY) Financials
RDY Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 4.5 billion | 1.3 billion |
2023-09-30 | 4.2 billion | 1.1 billion |
2023-06-30 | 4.1 billion | 675.4 million |
2023-03-31 | 3.9 billion | 1.1 billion |
RDY Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -3.7 million | 1.2 million |
2023-09-30 | 168.4 million | 1.2 million |
2023-06-30 | -11.2 million | 1.3 million |
2023-03-31 | 193.9 million | 255628 |
RDY Net Income
Date | Net Income |
---|---|
2023-12-31 | 165.6 million |
2023-09-30 | 178.2 million |
2023-06-30 | 171.1 million |
2023-03-31 | 304.4 million |
RDY Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 869.2 million | - | 44.5 million |
2023-09-30 | 816.3 million | 72.8 million | 43.1 million |
2023-06-30 | 746.1 million | - | 27.5 million |
2023-03-31 | 812.5 million | 15.6 million | 15.6 million |
RDY Shares Outstanding
RDY Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 60.6 million | 66.8 million | 243.0 million | - |
2023-09-30 | 47.4 million | 65.6 million | 347.5 million | - |
2023-06-30 | 148.5 million | 60.8 million | 215.9 million | - |
2023-03-31 | 45.6 million | 65.3 million | 155.3 million | 189.1 million |
RDY Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 866.7 million | 359.7 million |
2023-09-30 | 828.6 million | 342.4 million |
2023-06-30 | 822.0 million | 339.5 million |
2023-03-31 | 766.5 million | 137.7 million |
RDY
Price: $74.55
Dividend Yield: 0.55%
Forward Dividend Yield: 1.29%
Payout Ratio: 25.60%
Dividend Per Share: 0.97 USD
Earnings Per Share: 3.75 USD
P/E Ratio: 19.58
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 129000
Ebitda: 142.4 millionMarket Capitalization: 12.2 billion
Average Dividend Frequency: 1
Years Paying Dividends: 22
DGR3: 5.95%
DGR5: 5.95%
DGR10: 3.84%